Could adding a second drug boost bone strength in osteoporosis?

NCT ID NCT04467983

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at whether adding the drug abaloparatide (Tymlos) to the standard treatment denosumab (Prolia) can improve bone density more than denosumab alone in postmenopausal women with osteoporosis. Seventy women who have already been on denosumab will either continue with denosumab alone or add daily abaloparatide injections for 18 months. The main goal is to measure changes in bone density at the hip and spine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Abaloparatide (Tymlos) added to Denosumab (Prolia)
What this could lead to
If successful, this could show that adding abaloparatide to ongoing denosumab treatment significantly improves bone density in postmenopausal women with osteoporosis, offering a stronger treatment option.
What could go wrong
This is a small, early-phase 4 trial with only 70 participants, so results may not apply to everyone. Adding a daily injection may also increase side effects or be hard for patients to stick with.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOPOROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital for Special Surgery

    New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.